Impact of KRAS, BRAF and PI3KCA mutations in rectal carcinomas treated with neoadjuvant radiochemotherapy and surgery

被引:23
作者
Derbel, Olfa [1 ]
Wang, Qing [2 ]
Desseigne, Francoise [1 ]
Rivoire, Michel [3 ]
Meeus, Pierre [3 ]
Peyrat, Patrice [3 ]
Stella, Mattia [3 ]
Martel-Lafay, Isabelle [4 ]
Lemaistre, Anne-Isabelle [5 ]
de La Fouchardiere, Christelle [1 ]
机构
[1] Ctr Leon Berard, Dept Med Oncol, F-69008 Lyon, France
[2] Ctr Leon Berard, Dept Biopathol, F-69008 Lyon, France
[3] Ctr Leon Berard, Dept Surg, F-69008 Lyon, France
[4] Ctr Leon Berard, Dept Radiotherapy, F-69008 Lyon, France
[5] Ctr Leon Berard, Dept Anatomopathol, F-69008 Lyon, France
关键词
TOTAL MESORECTAL EXCISION; GENE COPY NUMBER; PREOPERATIVE RADIOTHERAPY; PATHOLOGICAL RESPONSE; PIK3CA MUTATION; POOR SURVIVAL; CANCER; CHEMORADIATION; FLUOROURACIL; LEUCOVORIN;
D O I
10.1186/1471-2407-13-200
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Background: Conventional treatment for locally advanced rectal cancer usually combines neoadjuvant radiochemotherapy and surgery. Until recently, there have been limited predictive factors (clinical or biological) for rectal tumor response to conventional treatment. KRAS, BRAF and PIK3CA mutations are commonly found in colon cancers. In this study, we aimed to determine the mutation frequencies of KRAS, BRAF and PIK3CA and to establish whether such mutations may be used as prognostic and/or predictive factors in rectal cancer patients. Methods: We retrospectively reviewed the clinical and biological data of 98 consecutive operated patients between May 2006 and September 2009. We focused in patients who received surgery in our center after radiochemotherapy and in which tumor samples were available. Results: In the 98 patients with a rectal cancer, the median follow-up time was 28.3 months (4-74). Eight out of ninety-eight patients experienced a local recurrence (8%) and 17/98 developed distant metastasis (17%). KRAS, BRAF and PIK3CA were identified respectively in 23 (23.5%), 2 (2%) and 4 (4%) patients. As described in previous studies, mutations in KRAS and BRAF were mutually exclusive. No patient with local recurrence exhibited KRAS or PIK3CA mutation and one harbored BRAF mutation (12.5%). Of the seventeen patients with distant metastasis (17%), 5 were presenting KRAS mutation (29%), one BRAF (5%) and one PIK3CA mutation (5%). No relationship was seen between PIK3CA, KRAS or BRAF mutation and local or distant recurrences. Conclusion: The frequencies of KRAS, BRAF and PIK3CA mutations in our study were lower than the average frequencies reported in colorectal cancers and no significant correlation was found between local/distant recurrences and KRAS, BRAF or PIK3CA mutations. Future studies with greater number of patients, longer follow-up time and greater power to predict associations are necessary to fully understand this relationship.
引用
收藏
页数:6
相关论文
共 37 条
[1]
Abdalla EK, 2004, ANN SURG, V239, P818, DOI 10.1097/01.sla.0000128305.90650.71
[2]
Patients With Initially Unresectable Colorectal Liver Metastases: Is There a Possibility of Cure? [J].
Adam, Rene ;
Wicherts, Dennis A. ;
de Haas, Robbert J. ;
Ciacio, Oriana ;
Levi, Francis ;
Paule, Bernard ;
Ducreux, Michel ;
Azoulay, Daniel ;
Bismuth, Henri ;
Castaing, Denis .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (11) :1829-1835
[3]
Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial [J].
Andre, Thierry ;
Boni, Corrado ;
Navarro, Matilde ;
Tabernero, Josep ;
Hickish, Tamas ;
Topham, Clare ;
Bonetti, Andrea ;
Clingan, Philip ;
Bridgewater, John ;
Rivera, Fernando ;
de Gramont, Aimery .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (19) :3109-3116
[4]
Primary Tumor Response to Preoperative Chemoradiation With or Without Oxaliplatin in Locally Advanced Rectal Cancer: Pathologic Results of the STAR-01 Randomized Phase III Trial [J].
Aschele, Carlo ;
Cionini, Luca ;
Lonardi, Sara ;
Pinto, Carmine ;
Cordio, Stefano ;
Rosati, Gerardo ;
Artale, Salvatore ;
Tagliagambe, Angiolo ;
Ambrosini, Giovanni ;
Rosetti, Paola ;
Bonetti, Andrea ;
Negru, Maria Emanuela ;
Tronconi, Maria Chiara ;
Luppi, Gabriele ;
Silvano, Giovanni ;
Corsi, Domenico Cristiano ;
Bochicchio, Anna Maria ;
Chiaulon, Germana ;
Gallo, Maurizio ;
Boni, Luca .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (20) :2773-2780
[5]
Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers [J].
Barault, Ludovic ;
Veyrie, Nicolas ;
Jooste, Valerie ;
Lecorre, Delphine ;
Chapusot, Caroline ;
Ferraz, Jean-Marc ;
Lievre, Astrid ;
Cortet, Marion ;
Bouvier, Anne-Marie ;
Rat, Patrick ;
Roignot, Patrick ;
Faivre, Jean ;
Laurent-Puig, Pierre ;
Piard, Francoise .
INTERNATIONAL JOURNAL OF CANCER, 2008, 122 (10) :2255-2259
[6]
Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy [J].
Bengala, C. ;
Bettelli, S. ;
Bertolini, F. ;
Sartori, G. ;
Fontana, A. ;
Malavasi, N. ;
Depenni, R. ;
Zironi, S. ;
Del Giovane, C. ;
Luppi, G. ;
Conte, P. F. .
BRITISH JOURNAL OF CANCER, 2010, 103 (07) :1019-1024
[7]
Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer [J].
Bengala, C. ;
Bettelli, S. ;
Bertolini, F. ;
Salvi, S. ;
Chiara, S. ;
Sonaglio, C. ;
Losi, L. ;
Bigiani, N. ;
Sartori, G. ;
Dealis, C. ;
Malavasi, N. ;
D'Amico, R. ;
Luppi, G. ;
Gatteschi, B. ;
Maiorana, A. ;
Conte, P. F. .
ANNALS OF ONCOLOGY, 2009, 20 (03) :469-474
[8]
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study [J].
Bokemeyer, C. ;
Bondarenko, I. ;
Hartmann, J. T. ;
de Braud, F. ;
Schuch, G. ;
Zubel, A. ;
Celik, I. ;
Schlichting, M. ;
Koralewski, P. .
ANNALS OF ONCOLOGY, 2011, 22 (07) :1535-1546
[9]
Chemotherapy with preoperative radiotherapy in rectal cancer [J].
Bosset, Jean-Francois ;
Collette, Laurence ;
Calais, Gilles ;
Mineur, Laurent ;
Maingon, Philippe ;
Radosevic-Jelic, Ljiljana ;
Daban, Alain ;
Bardet, Etienne ;
Beny, Alexander ;
Ollier, Jean-Claude .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (11) :1114-1123
[10]
Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer [J].
Bujko, K. ;
Nowacki, M. P. ;
Nasierowska-Guttmejer, A. ;
Michalski, W. ;
Bebenek, M. ;
Kryj, M. .
BRITISH JOURNAL OF SURGERY, 2006, 93 (10) :1215-1223